Teva Pharmaceutical Industries Ltd. TEVA had a busy week that included a major debt refinancing, a milestone shift in how its ...

CEO Richard Francis said the company has progressed from the initial phase of its “Pivot to Growth” plan into its next stage, ...

Today marks another meaningful milestone in Teva’s transformation,” said Richard Francis, President and CEO of Teva. “The trading of our ordinary shares on the NYSE is expected to broaden investor ...

Teva Pharmaceutical Industries Ltd. TEVA shares are trading higher after the company announced positive topline results from an ongoing Phase 2a study of TEV ‘408. The study met its primary endpoint.

Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.

Teva Pharmaceuticals is undergoing a strategic shift from generics to specialty branded medicines, complex generics, biosimilars, and innovation-led pipeline expansion. TEVA's key growth drivers ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Teva Pharmaceutical’s stock has quietly staged a powerful recovery, outpacing broader pharma benchmarks and forcing investors to revisit a name long written off as a value trap. With fresh legal ...

Teva Pharmaceutical (TEVA) stock surged Wednesday on bullish growth for its innovative drugs — Austedo, Ajovy and Uzedy — and plans to buy Tourette drugmaker Emalex Biosciences. Emalex is in ...

Teva (TEVA) snapped a six-session winning streak on Thursday, losing 0.6% to $36.52. The stock had been on track for a seventh straight session in the green but slipped into negative territory shortly ...